Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
To review the clinical safety experience of the monoclonal antibody IMC-C225, focusing on two clinically important adverse events: acne-like rash and allergic reactions. In addition, practical administration issues are discussed. Research articles. IMC-C225 administration is well tolerated and adverse events are mild and manageable. IMC-C225 can be safely and conveniently administered once weekly in outpatient settings. Because nurses will be involved with administration of IMC-C225 in the clinical setting, they must understand and be prepared to manage the acute and long-term adverse events associated with this agent.